Medicare-eligible patients diagnosed with atherosclerosis: Patterns in statin therapy and lipid monitoring

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1403-1411

  Ohsfeldt, Robert L ^a   Gandhi, Sanjay K ^b   Fox, Kathleen M ^c,d  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Atherosclerosis; Hypercholesterolemia; Lipoproteins; Medicare eligible; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL MONITORING; CHOLESTEROL BLOOD LEVEL; DRUG ACTIVITY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID MONITORING; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CHOLESTEROL, LDL; COMORBIDITY; ELIGIBILITY DETERMINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MEDICARE; MONITORING, PHYSIOLOGIC; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 67649422328     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902905658     Document Type: Article

References (24)

1. Faxon DP, Creager MA, Smith SC, et al. Atherosclerotic vascular disease conference: executive summary. Circulation 2004;109:2595-2604
2. Pasternak RC, Criqui MH, Benjamin EJ, et al. Atherosclerotic vascular disease conference: writing Group I: epidemiology. Circulation 2004;109:2605-2612 (Pubitemid 38720564)
3. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994;44:1046-1050 (Pubitemid 24188174)
4. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22
5. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008;62:1246-1254 (Pubitemid 351994084)
6. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388-391
7. Hiratzka LF, Eagle KA, Liang L, et al; for the Get With the Guidelines Steering Committee. Atherosclerosis secondary prevention performance measures after coronary bypass graft surgery compared with percutaneous catheter intervention and nonintervention patients in the Get With the Guidelines Database. Circulation 2007;116 (Suppl 1):207-212
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
9. Grundy SM, Cleeman JI, Merz CN, et al.: Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732
10. Brown BG, Hillger L, Zhai XQ, et al. Types of change in coronary stenosis and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment Study. Ann NY Acad Sci 1995;748:407-417
11. Nissen SE, Nicholls SJ, Sipahi I, et al., for the ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 2006;295:1556-1565
12. Crouse JR III, Raichlen JS, Riley WA, et al., for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007;297:1344-1353
13. Corti R, Fuster V, Fayad ZA, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005;46:106-112 (Pubitemid 40905137)
14. Yonemura A, Momiyama Y, Fayad ZA, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005;45:733-742 (Pubitemid 40278972)
15. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001;21:1623-1629 (Pubitemid 34215582)
16. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007;5:227-237
17. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467 (Pubitemid 30112269)
18. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol 2005;96:556-563 (Pubitemid 41132774)
19. Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood) 2007;26:630-643
20. Joyce GF, Goldman DP, Karaca-Mandic P, et al. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood) 2007;26:1333-1344
21. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002;40:675-685
22. Luthi JC, Troillet N, Eisenring MC, et al. Administrative data outperformed single-day chart review for comorbidity measure. Int J Quality Health Care 2007;19:225-231 (Pubitemid 47248945)
23. Malenka DJ, McLerran D, Roos N, et al. Using administrative data to describe casemix: a comparison with the medical record. J Clin Epidemiol 1994;47:1027-1032 (Pubitemid 24268912)
24. Kiechl S, Willeit J, for the Bruneck Study Group. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vas Biol 1999;19:1484-1490